

# **PROTEASES**

**Potential Role in Health and Disease**

**Edited by**

**Walter H. Hörl**

**and**

**August Heidland**

University of Würzburg  
Würzburg, Federal Republic of Germany

**PLENUM PRESS • NEW YORK AND LONDON**

~~6807747~~  
017760275  
01777312X  
007873693

---

Library of Congress Cataloging in Publication Data

International Symposium on Proteases: Potential Role in Health and Disease (1982: Würzburg, Germany)  
Proteases, potential role in health and disease.

(Advances in experimental medicine and biology; v. 167)

"Proceedings of the International Symposium on Proteases: Potential Role in Health and Disease, held October 17-20, 1982, in Würzburg, Federal Republic of Germany"—Verso t.p.

Includes bibliographical references and index.

1. Proteolytic enzymes—Congresses. 2. Proteolytic enzyme inhibitors—Congresses. I. Hörl, Walter H. II. Heidland, August. III. Series. [DNLM: 1. Protease inhibitors—Congresses. 2. Peptide hydrolases—Congresses. W1 AD559 v.167 / QU 136 I615P 1982]


QP609.P78157 1982

599'.019256

83-19186

ISBN 0-306-41488-0

---



GH 84 / 105

Proceedings of the International Symposium on Proteases: Potential Role in Health and Disease, held October 17-20, 1982, in Würzburg, Federal Republic of Germany

© 1984 Plenum Press, New York  
A Division of Plenum Publishing Corporation  
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

CONTENTS

PHYSIOLOGY AND PATHOPHYSIOLOGY OF PROTEASES  
AND THEIR INHIBITORS

Physiology and Pathophysiology of Neutral Proteinases of Human Granulocytes .....	1
K. Havemann and M. Gramse	
Regulation of Protease Activity .....	21
M. Steinbuch	
Human Kininogens and Their Function in the Kallikrein- Kinin Systems .....	41
W. Müller-Esterl and H. Fritz	
Possible Involvement of Kinins in Muscle Energy Metabolism .....	63
G. Dietze, E. Maerker, C. Lodri, R. Schiffman, M. Wicklmayr, R. Geiger, E. Fink, I. Boettger, H. Fritz, and H. Mehnert	
Structure and Function of Natural Inhibitors as Antagonists of Proteinase Activities .....	73
H. Tschesche	
Oxidation of Alpha-1-Proteinase Inhibitor: Significance for Pathobiology .....	89
J. Travis, K. Beatty, and N. Matheson	
In Vivo Significance of Kinetic Constants of Macromolecular Proteinase Inhibitors .....	97
J. G. Bieth	
On the Multiplicity of Cellular Elastases and their Inefficient Control by Natural Inhibitors .....	111
W. Hornebeck, D. Brechemier, M. P. Jacob, C. Frances, and L. Robert	

Proteases - Proteases Inhibitors: a Local Cellular Information System .....	121
H. Heine	

#### PROTEASES AND HORMONES

Regulatory Proteolysis during Corticosteroid Hormone Action .....	129
M. K. Agarwal	
Proteases in Hormone Production and Metabolism .....	141
W. A. Hsueh	
Precursor Processing and Metabolism of Parathyroid Hormone: Regulation by Calcium .....	153
J. A. Fischer	
Processing and Degradation of Met-Enkephalin by Peptidase Associated with Rat Brain Cortical Synaptosomes .....	165
W. Demmer and K. Brand	

#### PROTEASES IN KIDNEY AND INTESTINAL TRACT

Characterization and Clinical Significance of Membrane Bound Proteases from Human Kidney Cortex .....	179
J. E. Scherberich, C. Gauhl, G. Heinert, W. Mondorf, and W. Schoeppe	
Recent Advances in Protease Research using Synthetic Substrates .....	191
R. Gossrau, Z. Lojda, R. E. Smith, and P. Sinha	
Kinetic Characterization of Brush Border Membrane Proteases in Relationship to Mucosal Architecture by Section Biochemistry .....	209
S. Gutschmidt, R. Hoper, and R. Gossrau	
Fluorescence Detection of Proteases with AFC, AMC and MNA Peptides using Isoelectric Focusing .....	219
P. Sinha, R. Gossrau, R. E. Smith, and Z. Lojda	

## PROTEASES AND BLOOD SYSTEM

Pathophysiology of the Interaction between Complement and Non-Complement Proteases .....	227
U. E. Nydegger and S. Suter	
Interactions between the Alternative Complement Pathway and Proteases of the Coagulation System .....	235
M. D. Kazatchkine and M.-H. Jouvin	
The Calcium-Dependent Neutral Protease of Human Blood Platelets: a Comparison of its Effects on the Receptors for von Willebrand Factor and for the Fc-Fragment Derived from IgG .....	241
M. O. Spycher, U. E. Nydegger, and E. F. Luescher	
Alpha-2-Plasmin Inhibitor Inactivation by Human Granulocyte Elastase .....	253
M. Gramse, K. Havemann, and R. Egbring	
Heparin and Plasma Proteinase Inhibitors: Influence of Heparin on the Inhibition of Thrombin by $\alpha_2$ Macroglobulin .....	263
P. Lambin, F. Pochon, and M. Steinbuch	
The Involvement of Plasmatic and Fibrinolytic Systems in Idiopathic Glomerulo- nephritis (GN) .....	273
K. Andrassy, E. Ritz, and R. Waldherr	
The Effect of Aprotinin on Platelet Function, Blood Coagulation and Blood Lactate Level in Total Hip Replacement - a Double Blind Clinical Trial .....	287
S. Haas, R. Ketterl, A. Stemberger, P. Wendt, H.-M. Fritsche, H. Kienzle, F. Lechner, and G. Blümel	

## PROTEASES AND LUNG

Interaction of Granulocyte Proteases with Inhibitors in Pulmonary Diseases .....	299
K. Ohlsson, U. Fryksmark, M. Ohlsson, and H. Tegner	

Leukoproteinases and Pulmonary Emphysema: Cathepsin G and Other Chymotrypsin- Like Proteinases Enhance the Elasto- lytic Activity of Elastase on Lung Elastin .....	313
Ch. Boudier, Ph. Laurent, and J. G. Bieth	
Adult Respiratory Distress Syndrome (ARDS): Experimental Models with Elastase and Thrombin Infusion in Pigs .....	319
H. Burchardi, T. Stokke, I. Hensel, H. Köstering, G. Rahlf, G. Schlag, H. Heine, and W. H. Hörl	

#### PROTEASES AND ARTHRITIS

Interactions of Granulocyte Proteinases with Inhibitors in Rheumatoid Arthritis .....	335
L. Ekerot and K. Ohlsson	
Quantitation of Human Leukocyte Elastase, Cathepsin G, $\alpha$ -2-Macroglobulin and $\alpha$ -1-Proteinase Inhibitor in Osteo- arthrosis and Rheumatoid Arthritis Synovial Fluids .....	345
G. D. Virca, R. K. Mallya, M. B. Pepys, and H. P. Schnebli	
Plasma Levels of Inhibitor Bound Leukocytic Elastase in Rheumatoid Arthritis Patients .....	355
H. P. Schnebli, P. Christen, M. Jochum, R. K. Mallya, and M. B. Pepys	
$\alpha_2$ M-Pasebic Assay: a Solid Phase Immuno- sorbent Assay to Characterize Alpha <sub>2</sub> - Macroglobulin - Proteinase Complexes and the Proteinase Binding-Capacity of Alpha <sub>2</sub> -Macroglobulin .....	363
W. Borth	
Role of Alpha <sub>2</sub> -Macroglobulin: Proteinase Complexes in Pathogenesis of Inflammation: 'F' $\alpha_2$ M but not 'S' $\alpha_2$ M Induces Synovitis in Rabbits after Repeated Intra-Articular Administration .....	371
W. Borth and M. Susani	

## HYPERCATABOLISM

Enzyme-Linked Immunoassay for Human Granulocyte Elastase in Complex with $\alpha_1$ -Proteinase Inhibitor .....	379
S. Neumann, N. Henrich, G. Gunzer, and H. Lang	
Proteinases and their Inhibitors in Septicemia Basic Concepts and Clinical Implications .....	391
M. Jochum, K.-H. Duswald, S. Neumann, J. Witte, and H. Fritz	
Proteolytic Activity in Patients with Hypercatabolic Renal Failure .....	405
W. H. Hörl, R. M. Schäfer, K. Scheidhauer, M. Jochum, and A. Heidland	
Release of Granulocyte Neutral Proteinases in Patients with Acute and Chronic Renal Failure .....	417
A. Heidland, W. H. Hörl, N. Heller, H. Heine, S. Neumann, and E. Heidbreder	
Changes in Components of the Plasma Kallikrein- Kinin and Fibrinolytic Systems Induced by a Standardized Surgical Trauma .....	433
A. O. Aasen, J. Stadaas, T. E. Ruud, and P. Kierulf	
Endotoxins and Coagulation Parameters in Patients with Traumatic Haemorrhagic- and Bacterio- toxic Shock .....	439
A. Stemberger, F. Strasser, G. Blümel, B. v. Hundelshausen, S. Jelen, O. Schmidt, and G. Tempel	
Studies on Pathological Plasma Proteolysis in Severely Burned Patients using Chromogenic Peptide Substrate Assays: A Preliminary Report .....	449
T. E. Ruud, P. Kierulf, H. C. Godal, S. Aune, and A. O. Aasen	
Changes in Components of the Plasma Protease Systems Related to Course and Outcome of Surgical Sepsis .....	455
N. Smith-Erichsen, A. O. Aasen, and E. Amundsen	

## PANCREATITIS

Role of Proteases in the Development of Acute Pancreatitis .....	463
M. Wanke	
On the Potential Role of Trypsin and Trypsin Inhibitors in Acute Pancreatitis .....	477
A. Lasson and K. Ohlsson	
Studies on the Kallikrein-Kinin System in Plasma and Peritoneal Fluid during Experimental Pancreatitis .....	489
T. E. Ruud, A. O. Aasen, P. Kierulf, J. Stadaas, and S. Aune	
The Influence of the Kallikrein-Kinin System in the Development of the Pancreatic Shock .....	495
H. Kortmann, E. Fink, and G. Bönner	

## PROTEASES AND MUSCLE FUNCTION

Proteolytic Enzymes and Enhanced Muscle Protein Breakdown .....	505
B. Dahlmann, L. Kuehn, and H. Reinauer	
Ca <sup>2+</sup> -Activated Proteinases, Protein Degradation and Muscular Dystrophy .....	519
J. Kay	
Muscle Cathepsin D Activity, and RNA, DNA and Protein Content in Maintenance Hemo- dialysis Patients .....	533
G. F. Guarnieri, G. Toigo, R. Situlin, L. Faccini, R. Rustia, and F. Dardi	
Enhanced Muscle Protein Degradation and Amino Acid Release from the Hemicorpus of Acutely Uremic Rats .....	545
R. M. Flugel-Link, I. B. Salusky, M. R. Jones, and J. D. Kopple	
Enhanced Muscle Protein Catabolism in Uremia .....	557
H. R. Harter, T. A. Davis, and I. E. Karl	



CONTENTS

xv

Catabolic Stress on Intracellular Amino Acid  
Pool ..... 571  
P. Fürst

Rhabdomyolysis: a Clinical Entity for the  
Study of Role of Proteases ..... 581  
S. G. Massry

INDEX ..... 587

PLASMA LEVELS OF INHIBITOR-BOUND LEUKOCYtic ELASTASE IN  
RHEUMATOID ARTHRITIS PATIENTS

H. P. Schnebli<sup>1</sup>, P. Christen<sup>1</sup>, M. Jochum<sup>2</sup>,  
R. K. Mallya<sup>3</sup> and M. B. Pepys<sup>4</sup>

<sup>1</sup> Research Department, Pharma Division, Ciba-Geigy,  
CH-4002 Basel, <sup>2</sup> Abt. Klinische Chemie, Chirurgische  
Klinik, Universität München, D-8000 Munich. <sup>3</sup> Dept. <sup>4</sup>  
Rheumatology, Kings College Hospital, London, SE 5. <sup>4</sup>  
Immunological Medicine Unit, Dept. Medicine, Royal  
Postgraduate Medical School, London, W12, OH5

INTRODUCTION

It is generally agreed that: (a) massive numbers of PMN leukocytes accumulate at sites of chronic inflammation (1), and in inflammatory synovial fluids (2), (b) these PMN leukocytes release elastase (3) as well as a number of other enzymes and inflammatory mediators (4) during phagocytosis or other mechanisms (5), (c) substantial quantities of elastase have been identified in the synovium (6,7) or, complexed to naturally occurring inhibitors in synovial fluids of RA patients (8-12) or penetrated into the articular cartilage (13,14).

Without entering the debate as to whether or not leukocytic elastase is responsible for tissue destruction in RA and other inflammatory diseases (for a review see Barrett, ref. 15), we have taken the findings listed above to suggest that leukocytic elastase released at sites of inflammation may lead to elevated plasma levels of this enzyme.

Indeed, elevated plasma levels of leukocyte elastase -  $\alpha_1$ PI complexes have previously been observed (16) and subsequently<sup>1</sup> followed up in more detail (17) in patients with leukemia or septicaemia. Increased levels of elastase -  $\alpha_2$ M complexes were also found in septicaemic patients (18).

In the present study we measured the plasma levels of elastase -  $\alpha_1$ PI complexes by an immunological technique (ELISA) (Method A) and of  $\alpha_2$ M bound elastase with a synthetic chromogenic substrate (Method B) in RA patients (n=87) and healthy controls (n=24).

#### PATIENTS AND METHODS

Twenty seven male and 60 female patients suffering from rheumatoid arthritis according to the criteria of the American Rheumatism Association were studied. Their disease activity was assessed by a new multivariate analysis comprising the following criteria: morning stiffness, pain scale, grip strength, articular index, haemoglobin concentration and erythrocyte sedimentation rate (19). On the basis of their global score in the analysis the patients were assigned to one of four grades of disease activity (MDAG 1-4).

Blood samples were drawn into EDTA-coated tubes and centrifuged immediately in order to remove cells; plasma was then stored at  $-20^\circ$  until assayed.

Levels of immunoreactive elastase in plasma were determined with a newly developed enzyme-linked immunoassay (ELISA) (12,20). This method (Method A) measures exclusively the elastase complexed to  $\alpha_1$ PI. Plasma samples were incubated in plastic tubes coated with antibodies against elastase. After washing with buffer, the surface fixed elastase- $\alpha_1$ PI complexes were reacted with anti- $\alpha_1$ PI antibodies labelled with alkaline phosphatase. Under the conditions used, the enzymatic activity of the alkaline phosphatase (assayed with p-nitrophenyl phosphate) was proportional to the concentration of elastase- $\alpha_1$ PI complex in the sample. (For details of this assay, see ref. 20).

Leukocyte elastase activity in plasma was measured by a modification (18) of the procedure described earlier (21). In this assay (Method B) the release of p-nitroaniline from Methoxy-Succinyl-L-Ala-L-Ala-L-Pro-L-Val-p-Nitroanilide (MeO-Suc-Ala-Ala-Pro-Val-pNA), a highly specific chromogenic substrate for leukocytic elastase (22), was determined photometrically; o-phenanthroline was included to inhibit an unrelated metal dependent elastase-like enzyme (18, 23). Briefly, 0.2 ml of plasma was diluted with 0.2 ml of buffer containing the substrate and the metal chelator; final concentrations: 0.1 M Tris-HCl, pH 7.5, 1 mM MeO-Suc-Ala-Ala-Pro-Val-pNA and 10 mM o-phenanthroline. The mixture was incubated at  $37^\circ$  for 1 to 6 hours and the reaction was stopped by the addition of 1 ml trichloroacetic acid (7.5 %). Precipitated protein was removed by centrifugation and the released nitroaniline was transformed to an azo-dye by the sequential addition of 25  $\mu$ l each of sodium nitrite (1.8 %),

ammonium sulphamate (9 %) and N-1-naphtyl ethylene-diamine di-HCl (1.8 %) to the supernatant. The resulting color was measured at 550 nm. The corresponding enzyme activity is expressed in nmoles/ml/h of substrate hydrolyzed.

RESULTS AND DISCUSSION

The present study was undertaken to determine whether the release of leukocyte elastase at sites of active inflammation is reflected in the plasma levels of this enzyme, and whether this may be diagnostically useful in RA. Two independent methods for the determination of HLE plasma levels were employed.

The design of the enzyme-linked immunoassay (20) ensures that only HLE bound to  $\alpha_1$ -proteinase inhibitor was measured (Method A). In our hands, the HLE levels in control plasma were compatible with the previously published values of  $84 \pm 25$  ng/ml (20) and 60 ng/ml (median value) (24) using the same assay system.




Fig. 1 HLE plasma levels measured immunologically as  $\alpha_1$ PI complex in 87 RA patients: comparison with MDAG<sup>1</sup> (A), a weighted index of disease activity, or with the Ritchie articular index (B).

The majority of the plasma samples from RA patients had clearly elevated HLE- $\alpha_1$ PI levels (Fig. 1A); 65 of 87 samples revealed values more than 2 standard deviations above the normal mean value. However, as can be seen in the same figure, the HLE concentration in plasma does not correlate with the "mean disease activity grade (MDAG)" (19), a weighted index based on 6 disease

parameters (see patients and methods) or with the Ritchie articular index (25) alone (Fig. 1 B). Interestingly, in the same patient collective, C-reactive protein (CRP) levels correlated well, both with the MDAG and the Ritchie index (26).




Fig. 2 HLE plasma levels measured as enzymic activity of  $\alpha_2$ M complexes in 87 RA patients: comparison with MDAG (A) or with the Ritchie articular index (B).

The measurement of elastase activity in plasma (Method B) is based on the fact that  $\alpha_2$ M bound proteinases retain hydrolytic activity towards low  $M_2$  substrates, though they are unable to attack most large (protein) substrates. As shown previously with plasma from septicæmic patients (18), this elastase activity can be separated from the bulk of plasma proteins on Sephacryl S300. The apparent molecular weight (approx. 800 000 Da), the substrate specificity (MeO-Suc-Ala-Ala-Pro-Val-pNA) and the inhibition pattern (insensitive to EDTA and o-phenanthroline, sensitive to PMSF and the elastase specific inhibitor Eglin C) identifies this activity as leukocyte elastase- $\alpha_2$ M complex. Compared with plasma from 24 healthy controls, HLE activity was elevated in a number of plasma samples from RA patients (20 out of 87 samples were elevated more than 2 standard deviations above the normal mean) (Fig. 2A).

However, again no correlation could be found between plasma HLE activity levels and disease activity (Fig. 2). Furthermore the HLE- $\alpha_1$ PI levels (Method A) and the HLE- $\alpha_2$ M levels (Method B) did not correlate ( $R < 0.1$ , Fig. 3).

It must be stressed that the levels of elastase activity in plasma are very low, requiring a sensitive assay and prolonged reaction times (see methods). Normal plasma ( $n=24$ ) hydrolyze approximately  $0.9 \pm 0.3$  nmol MeO-Suc-Ala-Ala-Pro-Val-pNA per




Fig. 3: HLE- $\alpha_1$ PI levels and HLE- $\alpha_2$ M activities in plasma of 87 RA patients (note logarithmic transformation).

ml per hour. Although an extrapolation from this value to the amount of enzyme actually present as  $\alpha_2$ M complex is not permissible, it can be estimated to be about 1-2 ng elastase/ml plasma. This is much less than the 84 ng elastase/ml bound to  $\alpha_1$ PI in normal plasma (see above). However, these values are quite compatible, when the known rates of complex formation and elimination are taken into account: the association rate constant of elastase/ $\alpha_1$ PI is 1.5 to 2 fold higher than that of elastase/ $\alpha_2$ M (27); together with the much higher plasma concentration of  $\alpha_1$ PI (approx. 10 times in molar terms) this accounts for a 15-20 fold higher rate of formation of the elastase/ $\alpha_1$ PI complex compared with the formation of the elastase/ $\alpha_2$ M complex in plasma. Indeed, it was found that 90 % of a small amount of radiolabelled elastase added to human serum was bound to  $\alpha_1$ PI (28). The half-time of elimination of elastase- $\alpha_2$ M complexes in man is approx. 12 min, that of elastase - $\alpha_1$ PI is approx. 60 min (29).

Using these numbers for a simple computer simulation experiment we calculated an influx of 47 ng/ml/h of elastase into plasma (of healthy controls) creating steady state levels of elastase bound to  $\alpha_1$ PI and to  $\alpha_2$ M of 90 ng/ml and 0.9 ng/ml, respectively, - surprisingly close to our estimated values of 84 and 1 to 2 ng/ml.

These calculations, although to be interpreted with caution, point to another important consideration. The flux of 47 ng of elastase per ml plasma per hour would indicate a total turnover of HLE of 2 to 3 mg per day, which is far below the estimated value of 300-400 mg elastase assumed to be released as a consequence of the normal life span of PMN leukocytes in healthy persons (28). It must be concluded, therefore, that only a small part of the elastase present in the neutrophil granules ever reaches the circulation. This might be one reason for the lack of correlation of plasma HLE levels and disease activity as observed here. Other reasons may be inflammation related alteration of the clearance rate (reticulo endothelial system) and altered rates of synthesis and consumption of proteinase inhibitors ( $\alpha_1$ PI is an acute phase reactant).

It is concluded that, although HLE is substantially elevated in the plasma of many RA patients, the plasma concentration of this enzyme by itself cannot serve as an indicator of disease activity. It is possible, however, that in longitudinal studies (within the same patients) changes in plasma HLE levels may be indicative of disease progression; indeed, changes in plasma levels of HLE have previously been shown to be indicative of disease progression in septicaemia (17).

#### REFERENCES

1. W. Mohr, and D. Wessinghage, The relationship between polymorphonuclear granulocytes and cartilage destruction in rheumatoid arthritis, Z. Rheumatol. 37:81 (1978).
2. S. Ruddy, Synovial fluid: Mirror of the inflammatory lesion in rheumatoid arthritis, in: "Rheumatoid arthritis," E. D. Harris, ed., Medcom Press, New York (1974).
3. L. J. Ignarro, Regulation of lysosomal enzyme secretion: Role in inflammation, Agents and Actions 4:241 (1974).
4. P. M. Henson, Mechanisms of mediator release from inflammatory cells, in: "Mediators of Inflammation," G. Weissmann, ed., Plenum Press, New York (1974).
5. S. Honig, S. Hoffstein, and G. Weissmann, Leukocyte lysosomes and inflammation: The example of arthritis, Pathobiol. Annu. 8:315 (1978).
6. J. Saklatvala, A. J. Barrett, Identification of proteinases in rheumatoid synovium. Detection of leukocyte elastase, cathepsin G and another serine proteinase, Biochim. Biophys. Acta 615:167 (1980).

7. H. Menninger, R. Putzier, W. Mohr, D. Wessinghage, and K. Tillmann, Granulocyte elastase at the site of cartilage erosion by rheumatoid synovial tissue, Z. Rheumatol. 39:145 (1980).
8. F. S. Steven, A. Torre-Blanco, and J. A. A. Hunter, A neutral protease in rheumatoid synovial fluid capable of attacking the telopeptide regions of polymeric collagen fibrils, Biochim. Biophys. Acta 405:188 (1975).
9. G. D. Virca, H. P. Schnebli, R. K. Mallya, and M. B. Pepys, Quantitation of leukocyte elastase,  $\alpha_1$ -proteinase inhibitor and  $\alpha_2$ -macroglobulin in synovial fluid, in preparation.
10. G. P. Kerby, and S. M. Taylor, Enzymatic activity in human synovial fluid from rheumatoid and non-rheumatoid patients, Proc. Soc. Exp. Biol. Med. 126:865 (1976).
11. N. M. Hadler, J. K. Spitznagel, and R. J. Quinet, Lysosomal enzymes in inflammatory effusions, J. Immunol. 123:572 (1979).
12. K. Kleesiek, S. Neumann, and H. Greiling, Determination of the elastase  $\alpha_1$ -proteinase inhibitor complex, elastase activity and proteinase inhibitors in the synovial fluid, Fresenius Z. Anal. Chem. 311:434 (1982).
13. J. D. Sandy, A. Sriratana, H. L. G. Brown, and D. A. Lowther, Evidence for polymorphonuclear-leucocyte-derived proteinases in arthritic cartilage, Biochem. J. 193:193 (1981).
14. M. Velvart, K. Fehr, A. Baici, G. Sommermeyer, M. Knöpfel, M. Cancer, P. Salgam, and A. Böni, Degradation in vivo of articular cartilage in rheumatoid arthritis by leucocyte elastase from polymorphonuclear leucocytes, Rheumatol. Int. 1:121 (1981).
15. A. J. Barrett, The possible role of neutrophil proteinases in damage to articular cartilage, Agents and Actions 8:11 (1978).
16. R. Egbring, W. Schmidt, G. Fuchs, and K. Havemann, Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicaemia with coagulation defects, Blood 49:219 (1977).
17. M. Jochum, K. H. Duswald, E. Hiller and H. Fritz, Plasma levels of human granulocytic elastase- $\alpha_1$ -proteinase inhibitor complex (E- $\alpha_1$ PI) in patients with septicemia and acute leukemia, in: "Progress in Clinical Enzymology II," D. M. Goldberg and M. Werner, eds., Masson Publ., N.Y., in press (1982).
18. L. P. Nelles, M. Jochum, K. H. Duswald and H. P. Schnebli, Increased levels of two distinct elastase like hydrolases in plasma during septicaemia, in: "Progress in Clinical Enzymology II," D. M. Goldberg and M. Werner, eds., Masson Publ., N.Y., in press (1982).
19. R. K. Mallya, and B. E. W. Mace, The assessment of disease activity in rheumatoid arthritis using a multivariate analysis, Rheumatol. and Rehabil. 20:14 (1981).
20. S. Neumann, N. Hennrich, G. Gunzer, and H. Lang, Enzyme linked immuno-assay for human granulocyte elastase in complex with  $\alpha_1$ -proteinase inhibitor in plasma, J. Clin. Chem. Biochem. 19:232 (1981).



21. H. P. Schnebli, Adjuvant-induced inflammatory disease in the rat: Plasma levels of peptide hydrolases and protease inhibitors reflect disease activity, Agents and Actions 9:497 (1979).
22. K. Nakajima, J. C. Powers, B. M. Ashe, and M. Zimmermann, Mapping the extended substrate binding site of cathepsin G and human leucocyte elastase, J. Biol. Chem. 254:4027 (1978).
23. J. Saklatvala, Hydrolysis of the elastase substrate succinyl-trialanine nitroanilide by a metal-dependent enzyme in rheumatoid synovial fluid, J. Clin. Invest. 19:794 (1977).
24. D. Neumeier, A. Fateh-Moghadam und G. Menzel, Humane Granulozyten-Elastase. I. Zur Methodik einer enzymimmunologischen Bestimmung des Elastase- $\alpha_1$ -Proteinaseinhibitor-Komplexes, Fresenius Z. Anal. Chem. 311:389 (1982).
25. D. M. Ritchie, J. A. Boyle, J. M. McInnes, M. K. Jasani, T. G. Dalcos, P. Grieveason, and W. W. Buchanan, Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis, Q. J. Med. 147:393 (1968).
26. R. K. Mallya, F. C. deBeer, H. Berry, E. D. B. Hamilton, B. E. Mace, and M. B. Pepys, Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate, J. Rheumatol., in press.
27. G. D. Virca, and J. Travis, Kinetics of association of human leukocyte elastase and cathepsin G with human  $\alpha_2$ -macroglobulin, in preparation.
28. K. Ohlsson, and A. S. Olsson, Immunoreactive granulocyte elastase in human serum, Z. Physiol. Chem. 359:1531 (1978).
29. K. Ohlsson, and C. B. Laurell, The disappearance of enzyme-inhibitor complexes from circulation of man, Clin. Sci. Molec. Med. 51:87 (1976).

#### ACKNOWLEDGEMENT

We are grateful to Dr. S. Neumann and Dr. H. Lang (Merck, Darmstadt) for providing us with the materials for the ELISA assays.